




\$2,500,000 Operating Bridge

Summary of Indicative Terms · Trocar Pharma, Inc. · RadShield™ (YK-4-250)



Trocar Pharma is raising an immediate \$2,500,000 bridge to reopen and scale operations, rebuild the full-time team, and complete the development and regulatory work required to enter its \$37,500,000 and \$50,000,000 follow-on tranches from strength.

Terms of the Offering

Issuer	Trocar Pharma, Inc., a Maryland C-Corporation
Lead Asset	RadShield™ (YK-4-250) — first-in-class oral mitigator of Gastrointestinal Acute Radiation Syndrome (GI-ARS)
Offering	\$2,500,000 operating bridge — open now
Exemption	Regulation D, Rule 506(c) — verified accredited investors only
Security	Convertible note or preferred equity (final terms set with counsel at closing)
Minimum Investment	\$25,000; larger allocations welcome
Closing Mechanics	Rolling closings so capital funds operations before the round is fully subscribed
Subscription Window	60 days from launch
Verification	Third-party accreditation verification required under Rule 506(c)
Escrow	Subscription funds held in third-party escrow pending closing conditions
Investor Priority	Bridge participants are offered allocation in both follow-on tranches
Follow-On Tranche 1	\$37,500,000 — IND enablement; opens upon achievement of bridge milestones
Follow-On Tranche 2	\$50,000,000 — Phase 1/2 and procurement readiness; opens on IND clearance
Governing Documents	Private Placement Memorandum, subscription agreement and related governing documents
Jurisdiction	Maryland corporate law; offering conducted in permitted U.S. jurisdictions

Use of Bridge Proceeds

Category	Amount	Share
Core payroll & benefits	\$750,000	30%
Product / CMC completion	\$750,000	30%
Regulatory, quality & clinical planning	\$375,000	15%

Lab & preclinical studies	\$250,000	10%
Legal, financing & compliance	\$125,000	5%
Business development & investor relations	\$125,000	5%
Contingency / working capital	\$125,000	5%
Total	\$2,500,000	100%

Why This Bridge, Now

- 88% survival at 14.3 Gy versus 58% control in DoD/AFRRI GI-ARS studies.
- \$4.5M+ of DoD/AFRRI preclinical funding already deployed — government-generated data.
- FDA Pre-IND complete; Animal Rule pathway (21 CFR §314.610) confirmed.
- Georgetown University Exclusive License No. 2022-0493 and four U.S. patents.
- Zero FDA-approved therapies for the early lethal GI effects of radiation exposure.
- Oral, 24-hour post-exposure window; tablet or suspension, non-clinical administration.

Contact

TriUnity Capital Ventures, LLC · 6345 S. Pecos Rd., Suite 109, Las Vegas, NV 89120
invest@trocarpharma.finance · info@trocarpharma.finance · 702-929-9226

Disclaimer: This term sheet is a summary of indicative terms for discussion purposes only and is not a binding commitment, an offer to sell, or a solicitation of an offer to buy any security. Any offering is made solely pursuant to the Private Placement Memorandum and related governing documents, and only to verified accredited investors under Regulation D, Rule 506(c). Investments in early-stage pharmaceutical companies involve substantial risk, including complete loss of principal and illiquidity. Preclinical results are not predictive of clinical outcomes and no product described herein has been approved by the FDA.